Alkylguanine-DNA alkyltransferase as predictive factor of efficacy of dacarbazine+cisplatin+nidran regimen in patients with metastatic skin mela- noma
Abstract
Background. The goal of this study was to analyze significance of AGT expression as predictive marker of efficacy of Dacar bazine+Cisplatin+Nidran regimen in patients with metastatic skin melanoma Methods. 26 patients with metastatic skin melanoma were enrolled in the retrospective study. Immunohistochemical analysis of AGT expression was performed on paraffin-embedded tissue sections of primary tumor or available metastasis. Results. High AGT expression in tumor cells was associated with low efficacy of Dacarbazine+Cisplatin+Nidran regimen. Disease progression was observed in 85,7% patient with AGT-positive tumor and 29,4% - AGT-negative (р=0,023). There was a not significant difference of time without progression between two groups of patients. Conclusion. AGT expression could be potentially useful tool for predicting response of metastatic melanoma patients to Dacarbazine+Cisplatin+Nidran regimen.
About the Authors
Е. Степанова
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Russian Federation
Russian Federation
М. Абрамов
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Russian Federation
Russian Federation
А. Барышников
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Russian Federation
Russian Federation
М. Личиницер
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Russian Federation
Russian Federation
E. V. Stepanova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Science
Russian Federation
Russian Federation
M. E. Abramov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Science
Russian Federation
Russian Federation
A. Yu. Baryshnikov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Science
Russian Federation
Russian Federation
M. R. Lichinitser
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Science
Russian Federation
Russian Federation
References
1. Tsao H., Atkins M.B., Sober A.J. Management of cutaneous melanoma. N. Engl. J. Med. 2004, v. 351, p. 998-1012.
2. Coates A.S., Segelov E. Long term response to chemotherapy in patients with visceral metastatic Melanoma. Annals of Oncology. 1994, No. 5, p. 249-251.
3. Legha S.S., Ring S., Papadopoulos N. et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine and DTIC (CVD) for metastatic melanoma. Cancer. 1989, v. 64, p. 2024-2029.
4. Dolan M.E., Pegg A.E. 06-benzilguanine and its role in chemotherapy. Clin. Cancer Res. 1997, No. 3, p. 837-847.
5. Pegg A.E. Mammilian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990, v. 50, p. 6119-629.
6. Pegg A.E., Byers T.L. Repair of DNA containing 06-alkylguanine. FASEB J. 1992, No. 6, p. 2302-2310.
7. Egyhazi S., Margison G.P., Hansson J., Ringborg U. Immunohistochemical examination of the expression of 06-methylguanine-DNA methyltransferase in human melanoma metastases. Eur. J. Cancer. 1997, v. 33, No. 1, p. 129-134.
8. Ma S., Egyhazi S., Martenhed G. et al. Analysis of 06-methylguanine-DNA methyltransferase in melanoma tumors in patients treated with dacarbazine-based chemotherapy. Melanoma Res. 2002, v. 12, No. 4, p. 335-342.
9. Ma S., Egyhazi S., Ueno T., Lindhom C. et al. 06-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br. J. Cancer. 2003, v. 89, p. 1517-1523.
10. Hansson J., Martenhed G., Egyhazi S. et al. Analysis of 06-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction. Eur. J. Cancer. 1996, v. 32A, No. 13, p. 2319-2326.
11. Russel S.J., Ye Y.W., Waber P.G. et al. P53 mutations, 06-alkylguanina DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer. 1995, v. 75, p. 1339-1342.
12. Cayre A., Penault-Llorca F., De Latour M. et al. 06-methyl-guanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. Int. J. 0ncol. 2002, v. 21, No. 5, p. 1125-1131.
13. Balaca C., Ramirez J.L., Taron M. et al. 06-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-Bis(2-Chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin. Cancer Res. 2003, No. 9, p. 1461-1468.
14. D'Atri S., Graziani G., Lacal P.M. et al. Margison Attenuation of 06-Methylguanine-DNA Methyltransferase Activity and mRNA Levels by Cisplatin and Temozolomide in Jurkat Cells. Pharmacol. J. Exp. Ther. 2000, No. 8, p. 294.
15. Citron M., Decker R., Chen S. et al. 06-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res. 1991, v. 51, p. 4131-4134
Review
For citations:
, , , , Stepanova E.V., Abramov M.E., Baryshnikov A.Yu., Lichinitser M.R. Alkylguanine-DNA alkyltransferase as predictive factor of efficacy of dacarbazine+cisplatin+nidran regimen in patients with metastatic skin mela- noma. Bone and soft tissue sarcomas, tumors of the skin. 2011;(1):50-54. (In Russ.)
Views:
61
Email this article 
